Precision Medicine Online

Hutchmed Begins Phase I Trial of Second Antibody-Targeted Therapy Conjugate

NEW YORK – Hutchmed on Wednesday said it started a Phase I/IIa trial of its antibody-targeted therapy conjugate (ATTC) HMPL-A580 in patients with unresectable, advanced or metastatic solid tumors.
The New York Times

This Viral Deodorant Balm Is Proof No One Deodorant Fits All

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Abbie Kozolchyk Abbie Kozolchyk has tested and traveled with so many beauty ...
The Business Journals

Environmental Stewardship Foundation targets AKT land deal in fraud case

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Seeking to collect on a $24.7 ...
Women's Health

I Didn't Think Natural Deodorants Worked Until I Tried AKT

Women's Health may earn commission from the links on this page, but we only feature products we believe in. Why Trust Us? Yes, and AKT is my favorite whole body deodorant of 2025. Whole body ...
EurekAlert!

JMC | Insilico Medicine publishes AI-driven innovative design strategy for highly selective FGFR2/3 inhibitors

For years, developing selective FGFE2/3 inhibitors has been hindered by the extreme structural similarity among FGFR family members, leading to toxicities and resistance with current therapies.
Targeted Oncology

TYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBC

A groundbreaking trial for TYRA-300, an oral FGFR3 inhibitor, aims to transform treatment for patients with low-grade intermediate-risk bladder cancer. TYRA-300 is a potential first-in-class, ...
The Business Journals

AKT Development buys more than 200 acres in Rancho Murieta

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min AKT Development Corp. has made a ...
ascopubs.org

Inferring FGFR status from H&E images using digital pathology to identify patients for early-stage bladder cancer targeted therapies.

Prognostic impact of histological subtypes in non-muscle-invasive UTUC: Propensity matched analysis. Overall survival and biomarker results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab ...
ascopubs.org

Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies: A Pooled Analysis of Early-Phase Clinical Trials

FGFRi are effective treatment strategies for patients with advanced solid tumors harboring FGFR alterations, with manageable toxicities in most patients. FGFRi are a safe and effective treatment ...
Medscape

NICE Backs Oral Drug for Advanced Bladder Cancer

The National Institute for Health and Care Excellence (NICE) has recommended erdafitinib (Balversa, Johnson & Johnson) as a treatment option for adults with unresectable or metastatic urothelial ...
Nasdaq

HUTCHMED Completes Enrollment in Phase II Trial of Fanregratinib for Intrahepatic Cholangiocarcinoma Patients with FGFR2 Fusion/Rearrangement

HUTCHMED has announced the completion of patient enrollment in a Phase II trial for fanregratinib (HMPL-453), aimed at treating intrahepatic cholangiocarcinoma (IHCC) patients with FGFR2 ...